BioCARE Named as Distributor for COAGADEX® for the Treatment of Hereditary Factor X Deficiency

BioCARE Named as Distributor for COAGADEX® for the Treatment of Hereditary Factor X Deficiency

 

BioCARE announced that it has been named by Bio Products Laboratory Limited (BPL) as a distributor for Coagadex (coagulation factor X, human). Product is available for shipment.

Coagadex was approved by the U.S. Food and Drug Administration (FDA) on Oct. 20, 2015. Coagadex is the first and only FDA-approved product to treat hereditary factor X deficiency, and is the only factor X concentrate available in the U.S.

Factor X (“ten”) deficiency is a rare, inherited bleeding disorder caused by inadequate levels of clotting factor X protein in the blood. Similar to hemophilia A and hemophilia B, factor X deficiency is characterized by episodes of prolonged spontaneous bleeding. As one of the rarest bleeding disorders, it affects approximately 300 to 600 patients in the U.S. The goal of treatment in patients with hereditary factor X deficiency is to replace their missing factor X without adding other clotting factors the patients do not need.

“Being selected as a distributor of Coagadex shows the trust BPL has in the excellent services BioCARE provides for its customers,” said Linda Matthews, President of BioCARE.”  As a long-time supporter of the bleeding disorders community, we are excited to continue our partnership with BPL by distributing this ground-breaking product.”

To ensure a high level of service to providers of this patient community, BioCARE staff has received specialized disease state and Coagadex product training from BPL.

For full prescribing information for Coagadex visit: www.coagadex.com.